Probiotics in Liver Health Protection

Non-invasively detecting non-alcoholic fatty liver disease (NAFLD) in a subject by measuring the amount of Lactococcus lactis and/or Dorea sp. 5-2 microbial DNA in a biological sample from the subject and comparing it to a healthy control. Elevated levels of these microbes are biomarkers indicative of NAFLD.

Source

Compositions and methods for treating liver disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis by administering a consortium of isolated and purified microbial species to improve gut function and reduce liver injury markers. The microbial compositions are formulated in ingestible forms like pills, capsules, or powders. The compositions contain specific bacterial strains like Akkermansia muciniphila, Bifidobacterium, Clostridium, Eubacterium, and Faecalibacterium that produce beneficial short chain fatty acids. Administering these microbes reduces elevated liver enzymes, indicating improved liver health.

Source

A lactic acid bacterium called Weissella hellenica WiKim0103, isolated from Kimchi, with potential to prevent or improve fatty liver disease and inflammation. It showed an inhibitory effect on intracellular fat accumulation and reduction of fatty liver-related gene expression.

Source

Probiotic bacteria and composition for preventing and treating non-alcoholic fatty liver disease. The composition contains a specific strain of lactobacillus rhamnosus called LR-Y12. The composition is made by fermenting a traditional Chinese medicine compound extract containing pectin, dark plum fruit, medlar, cassia seed, ginseng, and dried ginger with the LR-Y12 probiotic. This composition has synergistic effects on body weight reduction, fatty liver relief, and liver protection.

Source

Strain of Lactobacillus formosan called Lt259 that has preventive and therapeutic effects on non-alcoholic fatty liver disease (NAFLD). The strain is isolated from human feces and shown to reduce liver pathology, improve liver function, lower cholesterol, triglycerides, and LDL, decrease inflammation markers, lower endotoxin levels, and regulate intestinal flora in rats with NAFLD. Lt259 has properties like hydrophobicity, self-aggregation, antioxidant ability, and resistance to antibiotics. The strain can be used in products to prevent, improve, or treat NAFLD, hyperlipidemia, inflammation, and intestinal flora imbalances.

Source

Using Lactobacillus plantarum J26 strain and a composition containing it to alleviate acute-on-chronic alcoholic liver injury. The strain, isolated from kimchi, has good alcohol tolerance and intestinal colonization properties. It reduces alcohol-induced liver cell apoptosis, oxidative stress, inflammation, and intestinal damage. Compounding J26 with plants like kudzu root, vine tea, fructooligosaccharides, and hyaluronic acid further improves the effect.

Source

Pediococcus pentosaceus strain A21243 that reduces fat accumulation and treats non-alcoholic fatty liver disease. The strain can lower fat levels, inhibit cholesterol synthesis, promote bile acid synthesis, improve glucose tolerance, and reduce insulin resistance in models of non-alcoholic fatty liver disease. It also reduces liver damage, inflammation, and cholestasis. The strain is useful in medicines for preventing/treating non-alcoholic fatty liver disease, fat reduction, and metabolic dysfunction associated with non-alcoholic fatty liver.

Source

Using Lactobacillus plantarum strain A21094 to prevent and treat non-alcoholic fatty liver disease. The strain improves liver tissue morphology, lowers cholesterol and triglycerides, reduces inflammation, and enhances glucose tolerance. It achieves these effects by inhibiting cholesterol synthesis, promoting bile acid synthesis, regulating fatty acid synthesis, and suppressing inflammatory signaling.

Source

Lactobacillus plantarum ZJUIDS14 for improving non-alcoholic fatty liver disease. The lactobacillus plantarum is inhibiting the reproduction of other harmful germs in intestines and stomach, keep and ensure the best advantage composition of beneficial germs and the stability of the composition, block the colonization and invasion of pathogenic germs, inhibit the growth and development of pathogenic germs and harmful microorganism strains and the adhesion of endotoxin.

Source

Probiotic composition containing Lactobacillus acidophilus LA-G80 and Bifidobacterium bifidum BB-G90 strains for liver protection. The composition can reduce liver damage markers, improve liver function, and normalize inflammatory responses in liver injury models. It also optimizes gut microbiota and boosts immunity. The strains are lactic acid bacteria isolated from elderly and healthy individuals, respectively.

Source

A probiotic composition containing specific strains of Lactobacillus acidophilus (LA85) and Bifidobacterium longum (BL21) in a 1:1 ratio for improving chronic alcohol-induced liver disease. Administering this probiotic composition to mice with chronic alcohol-induced liver disease reduced liver lipid accumulation, liver damage, and alcohol-induced hepatocyte apoptosis compared to the mice only consuming alcohol.

Source

A probiotic composition containing specific strains of lactic acid bacteria to improve alcoholic fatty liver disease. The composition includes Lactobacillus rhamnosus strain LRa05 and Lactobacillus plantarum strain Lp05. Administering these probiotics can prevent, alleviate, or treat alcoholic fatty liver disease, chronic liver injury, liver fibrosis, cirrhosis, or liver cancer. The probiotics improve alcoholic fatty liver by reducing inflammation, oxidative stress, serum triglycerides, and intestinal permeability.

Source

Lactobacillus paracasei strain isolated from yak yogurt that alleviates alcohol-induced liver and gastric injury. The strain improves antioxidant capability in liver and gastric tissue, prevents inflammation, and recovers tissue structure. It also prolongs drunkenness time and shortens sober-up time. The strain can be used in preparations for preventing drunkenness, alleviating hangovers, reducing liver and gastric injury, and improving antioxidant and anti-inflammatory responses.

Source

Lactobacillus fermentum strain A21252 that relieves hangover, protects the liver, resists oxidative damage, and reduces digestive tract damage. The strain has characteristics like Lactobacillus fermentum and is isolated from the feces of a centenarian. It survives in simulated gastric and intestinal fluids. The strain degrades ethanol in vitro and in vivo, increases alcohol and acetaldehyde dehydrogenase activities, reduces liver tissue damage from drinking, protects liver function, reduces oxidative stress, and reduces digestive tract damage from alcohol.

Source

A strain of Lactobacillus reuteri, CCFM1132, that is capable of relieving hyperuricemia as well as a pharmaceutical composition containing the strain. The strain can reduce serum uric acid levels, inhibit liver xanthine oxidase activity, reduce creatinine levels, reduce serum triglycerides, reduce alkaline phosphatase activity, and increase expression of the ileum uric acid transporter ABCG2.

Source

A composition for improving hepatic function using a green tea-derived Lactiplantibacillus plantarum strain. It can be used to prevent and treat fatty liver disease. The strain, culture, lysate or extract of the Lactiplantibacillus plantarum is administered to improve liver health.

Source

Using a specific strain of Lactobacillus plantarum bacteria called P9 to prevent and treat non-alcoholic fatty liver disease (NAFLD). The strain P9 restores intestinal barrier integrity, reduces inflammation, and improves liver function in a mouse model of NAFLD. P9 supplementation offsets defects in intestinal barrier function, maintains intestinal homeostasis, and regulates immune responses to prevent translocation of endotoxins and inflammatory molecules into the liver. It also modulates gut microbiota composition and alters gene expression pathways like p53 and PPAR-a to maintain lipid metabolism homeostasis.

Source

Protecting alcoholic liver injury. The composition comprises lactobacillus paracasei JN-8 freeze-dried bacterial powder, polyphenol compounds and vitamins, wherein the lactobacillus paracasei JN-8 is preserved in China general microbiological culture Collection center (China general microbiological culture Collection center) at the 21 st month of 2021, and the preservation address is no.

Source

Using Megalococcus escherichia, a bacterial strain found in the human gut, for preventing and treating fatty liver, protecting liver function, and improving liver health. The strain, named Megalococcus escherichia, has liver-protective effects when administered to animals with fatty liver induced by a high-fat diet. The bacterial strain improves steatosis, reduces triglyceride deposition, improves gene expression related to cholesterol transport, and repairs liver damage. It shows potential as a probiotic and supplement for preventing and treating fatty liver and protecting liver health.

Source

Probiotic composition for relieving non-alcoholic fatty liver disease. The composition contains specific strains of lactic acid bacteria, including Lactobacillus plantarum HA-119, Lactobacillus casei Rosell-0215, and Lactobacillus rhamnosus Rosell-0052, in a specific ratio. The composition aims to alleviate non-alcoholic fatty liver disease by modulating intestinal flora to reduce liver inflammation and improve liver function. The composition can be used in functional foods, beverages, and supplements to manage non-alcoholic fatty liver disease.

Source

A strain of Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) called 4F225 that provides liver protection against alcohol-induced damage. The strain reduces alcohol-induced weight loss, prevents liver cell morphological changes, lowers liver function markers, inflammatory cytokines, and oxidative stress. It enhances antioxidant capacity and genes related to lipid and oxidative metabolism. The strain's hepatoprotective effects are attributed to its antioxidant and anti-inflammatory activities.

Source

Lactobacillus gasseri strain SWPM102 for preventing, treating, and reducing symptoms of metabolic diseases like obesity and fatty liver. The strain has effects like weight loss, reduced body fat, smaller fat cells, less liver steatosis, lower inflammation, lower leptin, and higher adiponectin. It can be used in pharmaceuticals, foods, and compositions for obesity and fatty liver prevention/treatment.

Source

A lactic acid bacterial composition for treating or preventing jaundice that includes Bifidobacterium animalis subsp. lactis CP-9 strain and Lactobacillus salivarius subsp. salicinius AP-32 strain. Administering these strains to inhibit E.coli growth and treat/prevent jaundice.

Source

Preventing or treating liver injury in people with hyperlipidemia. The medicine is used for preventing or treating liver injury, including liver injury caused by hyperlipidemia. The medicine contains lactobacillus plantarum BX62 in reducing fat accumulation or cell swelling of liver, reducing neutral fat accumulation in liver cells or improving GSH-Px activity and CAT activity, and can synergistically increase GSH-Px activity and CAT activity.

Source

Lactobacillus metagen in preparation of a medicament for preventing and/or treating alcoholic liver disease. The metagen is prepared by mixed fermentation of lactobacillus reuteri (Lactobacillus reuteri), lactobacillus acidophilus (Lactobacillus acidophilus) and lactobacillus rhamnosus (Lactobacillus rhamnosus).

Source

Compositions and methods for treating cholestatic diseases, such as primary sclerosing cirrhosis, primary biliary cirrhosis, progressive familial intrahepatic cholestasis, non-alcoholic steatohepatitis, cholestasis of pregnancy, cholangitis, hepatitis, alcoholic liver disease, hepatocellular carcinoma, liver cirrhosis, cystic fibrosis, graft-vs-host disease, and obstructive cholestasis. The compositions contain specific bile acid-metabolizing bacteria that can deconjugate bile salts and modulate bile acid signaling in the gastrointestinal tract to prevent toxic bile acid buildup and liver damage.

Source

Use of Lactobacillus helveticus ZJUIDS12 to prevent and treat alcoholic liver disease. The Lactobacillus helveticus strain can reduce liver damage from alcohol consumption. It does this by improving gut barrier function, reducing liver fat accumulation, and improving antioxidant capacity. The strain also has bile salt hydrolase activity which may help lower blood sugar levels.

Source

Lactobacillus fermentum strain grx08 for alleviating alcoholic liver injury and related symptoms. The strain has been shown to improve alcohol metabolism, reduce oxidative stress, lower inflammation, and mitigate kidney damage in animal models of acute alcohol injury. It can potentially be used in foods, functional foods, and medicines to mitigate alcohol-induced liver and systemic harm.

Source

A Lactobacillus lactis strain and composition for preventing or treating non-alcoholic fatty liver disease. The strain, Lactobacillus lactis CKDB001, was isolated from milk and found to reduce fatty liver and inflammation when administered to mice with high-fat diet-induced fatty liver disease.

Source

Composition for protecting the liver and relieving alcohol consisting of specific strains of bacteria, prebiotics, and flavoring agents. The composition contains Bifidobacterium adolescentis, Lactobacillus plantarum, Lactobacillus rhamnosus, stachyose, and 2'-fucosyllactose. The bacteria strains promote beneficial gut flora growth and suppress harmful bacteria. The prebiotics feed the bacteria strains. The composition aims to protect the liver and relieve alcohol-induced effects by regulating intestinal flora and reducing alcohol absorption.

Source

A lactic acid bacterial composition for treating or preventing jaundice, using specific strains of Bifidobacterium animalis subsp. lactis and Lactobacillus salivarius subsp. salicinius.

Source

Preventing, improving or treating alcoholic fatty liver. The prevention is achieved by administering a Lactobacillus fermentum MG4237 strain, a culture medium or a cell-free extract thereof.

Source

Lactobacillus brevis ( Lactobacillus brevis ) MG5311 strain and a composition for preventing, improving or treating alcoholic fatty liver. The composition includes a pharmaceutical composition, food or health functional food composition, and a cell-free extract thereof.

Source

A strain of lactic acid bacterium, Lactobacillus pentosus CQZC02, that has protective effects against alcoholic liver injury. The bacterium can alleviate alcohol-induced weight loss, liver weight and index increase, accelerate alcohol metabolism, reduce inflammation, promote lipid metabolism, and increase antioxidant levels in mice with alcoholic liver damage. This provides a basis for developing functional foods to prevent and treat alcoholic liver disease using Lactobacillus pentosus CQZC02.

Source

Compound probiotic bacterium containing specific strains of Bifidobacterium animalis subsp. lactis, Lactobacillus gasseri, and Lactobacillus plantarum. This compound probiotic has been shown to prevent and treat acute liver injury in animal models. The probiotics upregulate the expression of the growth factor amphiregulin (Areg) which reduces liver damage and promotes repair.

Source

Composition and diagnosis kit for diagnosing and preventing alcoholic fatty liver disease. The composition uses a Roseburia intestinalis strain that improves fatty liver symptoms. The kit measures the strain in fecal samples to diagnose disease.

Source

Preventing, improving, or treating non-alcoholic fatty liver disease (NAFLD) using a specific strain of Lactobacillus delbrueckii subsp. lactis called CKDB001. The strain reduces NAFLD and inflammation when administered to mice with the condition. The strain can be formulated into compositions for preventing or treating NAFLD, as well as in food products to prevent or improve NAFLD.

Source

Composite probiotic containing specific strains of Bacillus, Enterococcus, and Lactobacillus bacteria that can prevent, improve, or treat metabolic diseases like obesity, diabetes, and fatty liver. The composite probiotic has an optimal mixing ratio of the strains Bacillus bellegensis (Bacillus velezensis), Bacillus Richenipomis (Bacillus licheniformis), Enterococcus phyceum (Enterococcus faecium), and Lactobacillus plantarum (Lactobacillus plantarum). The composite probiotic has antioxidant and anti-inflammatory effects, as well as suppressing obesity by increasing energy metabolism.

Source

Probiotic preparation that can be used for developing and applying daily fat-reducing and liver-protecting health-care products. The preparation includes firstly, mixing prebiotics with each other according to a certain proportion; secondly, packaging MRS cholesterol culture medium into test tubes at a volume of 5ml per tube, and adding 0.2 10 of probiotic bacteria 8 inoculating at the concentration of CFU/mL, using uninoculated as experimental control, culturing at 37 °C in anaerobic environment for 12h, and calculating the degradation rate of cholesterol according to the method of example 1.

Source

Lactococcus lactis subsp. lactis CCFM1018, a probiotic strain that can be used in food and medicine to help excrete the plasticizer di(2-ethylhexyl) phthalate (DEHP) from the body. DEHP is a common plasticizer that can leach from plastic products into the environment and human body, causing toxicity. The strain was found to bind and metabolize DEHP in the gut, reducing its absorption and promoting fecal excretion.

Source

Engineered bacteria to treat liver disease like hepatic encephalopathy and NASH/NAFLD. The bacteria can be administered to the gut to reduce inflammation and ammonia levels in the gut and liver. The bacteria are genetically modified to consume excess ammonia and convert it into alternate byproducts like arginine. They also reduce inflammation by decreasing expression of genes like IL-6 and TNF-alpha in the gut and liver.

Source

Using a strain of lactic acid bacterium, Pediococcus lactis CCFM1105, to mitigate the toxic effects of the perfluorinated compound PFOS. The bacterium has been found to adsorb PFOS, scavenge free radicals, and improve antioxidant capacity in the presence of PFOS. It also reduces liver enzyme levels, inflammation, and oxidative stress in mice exposed to PFOS. Consuming Pediococcus lactis CCFM1105 or fermented foods made with it may help alleviate the health risks of PFOS exposure.

Source

Composition and method to prevent or treat liver injury like nonalcoholic fatty liver disease (NAFLD). The composition contains a strain of Ruminococcus bacteria that can be administered as a food supplement or pharmaceutical. The Ruminococcus strain helps alleviate liver injury when given to subjects with conditions like NAFLD.

Source

A health food and pharmaceutical composition for improving liver function using novel strains of bacteria. The strains are Lactobacillus pentosus KF8, Bacillus subtilis KF11, and Lactococcus lactis KF140. The composition contains these strains, their lysates, or culture products as active ingredients. The strains inhibit liver damage indicators like ALT and AST, reduce liver cholesterol and triglycerides, and prevent fat accumulation.

Source

A composition containing the Lactobacillus mudanjiangensis CKDB001 strain for preventing, treating, or improving non-alcoholic fatty liver disease, obesity, and dyslipidemia. The composition uses a specific strain of Lactobacillus bacteria to address metabolic disorders like NAFLD, obesity, and high cholesterol. The CKDB001 strain has been shown to reduce fatty liver, triglycerides, and cholesterol levels in mouse models of these conditions.

Source

Lactococcus chungangensis strain CAU 1447 for preventing or treating alcoholic liver disease, liver damage, and hangover symptoms. The strain is isolated from kimchi and has enzymes to metabolize alcohol and acids for intestinal survival. It shows improved liver function, reduced inflammation, and antioxidant effects in animal models of alcoholic liver disease.

Source

Diagnosing and treating fungal dysbiosis in the gut of cirrhosis patients by analyzing bacterial taxa in gut samples. Comparing the bacterial profile to control profiles can predict fungal dysbiosis. This allows targeted treatment for fungal overgrowth, avoiding unnecessary antibiotics, using probiotics/fecal transplants, and reducing re-hospitalization risk.

Source

Use of a Leuconostoc citreum bacteria strain to prevent and treat fatty liver disease. The strain, isolated from traditional fermented foods, inhibits fat accumulation and inflammation in liver cells and improves liver function. The strain can be formulated into compositions like foods, supplements or pharmaceuticals for prevention and treatment of fatty liver, obesity and related conditions like liver fibrosis.

Source

A probiotic strain that can delay aging by improving mitochondrial activity and gene expression in liver, muscle, and nerve cells. The strain is Lactobacillus plantarum TCI999, which increases CCT gene expression in liver cells, Pink1, Parkin, and Atg gene expression in muscle cells, and Pink1, Parkin, and Atg gene expression in nerve cells. The strain also regulates NAD+ and telomere activity. The strain can be used in food, drink, supplements, or pharmaceuticals to delay aging.

Source

Using a novel Lactobacillus fermentum strain, GB102, for preventing and treating metabolic diseases like obesity, diabetes, and fatty liver. The strain reduces fat accumulation in white and brown adipose tissue, lowers blood glucose levels, improves insulin sensitivity, and regulates metabolic hormones. Oral administration of the strain to obese mice prevented obesity, insulin resistance, and fatty liver.

Source